What is Intact Genomics?
Operating as an ISO 13485:2016 certified enterprise, Intact Genomics serves as a critical infrastructure provider for the scientific community. The company specializes in the development and distribution of high-quality life science products, including specialized enzymes, competent cells, and advanced cloning kits. With a client base exceeding 2,000 laboratories worldwide, the firm facilitates essential research across human health, agricultural biotechnology, and environmental sustainability. Their core competencies in DNA and RNA amplification, coupled with sophisticated gene editing and protein expression services, position them as a vital partner for researchers requiring rigorous quality standards and rapid logistical support.
How much funding has Intact Genomics raised?
Intact Genomics has raised a total of $314K across 2 funding rounds:
Debt
$150K
Debt
$164K
Debt (2020): $150K with participation from PPP
Debt (2021): $164K led by PPP
Key Investors in Intact Genomics
PPP
Public-Private Partnership
What's next for Intact Genomics?
With the recent influx of capital, Intact Genomics is well-positioned to accelerate its research and development initiatives and further optimize its supply chain efficiency. The company's focus on late-stage growth suggests a strategic pivot toward scaling its custom genomic services to meet the increasing demand for precision medicine and synthetic biology applications. By maintaining its commitment to expert technical support and high-throughput manufacturing, the firm is poised to capture additional market share, potentially diversifying its product portfolio to address emerging challenges in genomic diagnostics and therapeutic development. This financial backing provides the necessary runway to sustain long-term innovation in an increasingly data-driven biotech sector.
See full Intact Genomics company page
